Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Area of Science:

• Biomedical Engineering
• Immunotherapy
• Nanotechnology

Background:

• Cell therapies face challenges with transplanted cell survival and function.
• Adjuvant drugs often have systemic side effects when administered conventionally.

Purpose of the Study:

• To develop a novel strategy to improve cell therapy efficacy.
• To enhance therapeutic cell viability and function post-transplantation.
• To minimize systemic toxicity associated with adjuvant drugs.

Main Methods:

• Conjugating adjuvant drug-loaded nanoparticles to the surface of therapeutic cells.
• Utilizing sustained pseudoautocrine stimulation for donor cell support.
• Evaluating therapeutic outcomes in cancer adoptive T cell therapy models.
• Assessing hematopoietic stem cell graft repopulation in vivo.

Main Results:

• Marked enhancement in tumor elimination was observed in adoptive T cell therapy.
• Increased in vivo repopulation rate of hematopoietic stem cell grafts was achieved.
• Low doses of adjuvant drugs, ineffective systemically, showed efficacy when nanoparticle-conjugated.
• The strategy minimized systemic side effects of adjuvant drugs.

Conclusions:

• Conjugating drug-loaded nanoparticles to therapeutic cells is a simple and generalizable strategy to enhance cell therapy.
• This method improves therapeutic cell performance and reduces systemic drug toxicity.
• Therapeutic cells can serve as effective vectors for targeted drug delivery.